Clinical trial

A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in…

NCT00399724 · Sanofi, Industry · Completed

Key facts

NCT number NCT00399724
Title A Trial Comparing Lantus Algorithms to Achieve Normal Blood Glucose Targets in Subjects With Uncontrolled Blood Sugar With Type 2 Diabetes Mellitus
Official title A Multicentre, Multinational, Randomised, Open Study to Establish the Optimal Method for Initiating and Maintaining Lantus® (Insulin Glargine) Therapy Based on a Comparison of Two Treatment Algorithms to Determine Optimal Metabolic Outcomes, Safety, and Satisfaction in Subjects With Type 2 Diabetes…
Acronym AT-LANTUS
Lead sponsor Sanofi, Industry
Status Completed
Phase Phase 4
Study type Interventional
Conditions Diabetes Mellitus, Type 2
Intervention type Drug
Interventions Insulin glargine
Enrollment 7,376
Start date Mar 1, 2002
Primary completion Aug 1, 2003
Completion Aug 1, 2003
First posted Nov 15, 2006
Last update posted Aug 31, 2010

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies